Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Cell-mediated Immune Responses

Cell-mediated Immune Responses

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Switching between complement inhibitors in paroxysmal nocturnal hemoglobinuria: Analysis of strategy, efficacy, and safety.

HemaSphere·2026

Same author

International Survey for Antiemetics in Hematopoietic Stem Cell Transplantation in the APBMT Centers.

Blood cell therapy·2026

Same author

Anti-obesity effects of <i>Withania somnifera</i> and <i>Chrysanthemum zawadskii</i> Herbich var. <i>latilobum</i> (Maxim.) Kitamura by regulating lipid metabolism and insulin signaling in 3T3-L1 adipocytes.

Nutrition research and practice·2026

Same author

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·2026

Same author

Eustachian tube dysfunction in adults.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·2025

Same author

Efficacy and safety of vemircopan as monotherapy in patients with paroxysmal nocturnal hemoglobinuria.

Blood advances·2025

Search research articles

Related Experiment Video

Updated: May 12, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

The optimal immunosuppressive therapy for aplastic anemia.

Seung Hwan Shin¹, Jong Wook Lee

¹Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 505 Banpo-Dong, Seocho-Gu, Seoul 137-701, Republic of Korea.

International Journal of Hematology

|April 23, 2013

Summary

Immunosuppressive treatment (IST) is standard for aplastic anemia (AA) but faces challenges. This review explores AA pathophysiology, current IST, and novel strategies to improve patient outcomes.

More Related Videos

Killer Artificial Antigen Presenting Cells (KaAPC) for Efficient In Vitro Depletion of Human Antigen-specific T Cells

Killer Artificial Antigen Presenting Cells (KaAPC) for Efficient In Vitro Depletion of Human Antigen-specific T Cells

Published on: August 11, 2014

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

Related Experiment Videos

Last Updated: May 12, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Killer Artificial Antigen Presenting Cells (KaAPC) for Efficient In Vitro Depletion of Human Antigen-specific T Cells

Killer Artificial Antigen Presenting Cells (KaAPC) for Efficient In Vitro Depletion of Human Antigen-specific T Cells

Published on: August 11, 2014

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

Area of Science:

Hematology
Immunology
Oncology

Background:

Aplastic anemia (AA) is a rare bone marrow failure disorder.
Immunosuppressive treatment (IST) is the primary therapy for AA patients ineligible for stem cell transplantation.
Horse anti-thymocyte globulin (ATG) and cyclosporine A (CsA) combination is the standard IST regimen.

Purpose of the Study:

To review the immune-mediated pathophysiology of AA.
To discuss the efficacy and limitations of current IST regimens.
To explore emerging therapeutic strategies for AA.

Main Methods:

Literature review of recent studies on AA pathophysiology and treatment.
Analysis of clinical outcomes for standard and novel IST regimens.
Discussion of ongoing clinical trials and alternative agents.

Main Results:

Standard IST (horse ATG/CsA) shows satisfactory results but treatment failure (unresponsiveness, relapse, clonal evolution) persists.
Research is ongoing to overcome IST limitations, but no definitive solutions have emerged.
Alternative agents like alemtuzumab and eltrombopag show promise.

Conclusions:

Understanding AA's immune basis is crucial for targeted therapy.
Improving IST efficacy and managing treatment failure remain critical challenges in AA management.
Novel agents and treatment combinations offer hope for better outcomes in AA patients.